{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:38:15Z","timestamp":1787870295512,"version":"build-2784847793"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA043408"],"award-info":[{"award-number":["R01DA043408"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Institutes of Health Research (CIHR) Doctoral Research Award"},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Science","doi-asserted-by":"crossref","award":["P20GM125507"],"award-info":[{"award-number":["P20GM125507"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA037190"],"award-info":[{"award-number":["R25DA037190"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute on Mental Health","doi-asserted-by":"crossref","award":["R34MH12455"],"award-info":[{"award-number":["R34MH12455"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec016\">\n<jats:title>Background<\/jats:title>\n<jats:p>People living with HIV (PLHIV) who use drugs face overlapping social-structural inequities that contribute to suboptimal adherence to antiretroviral therapy (ART). Recent research suggests that long-acting antiretroviral therapy (LA-ART) can offer an important alternative to daily oral ART by mitigating adherence barriers, but this work has largely excluded PLHIV who use drugs. We, therefore, explored the acceptability of injectable and transdermal LA-ART among PLHIV who use drugs in Canada, which has no-cost universal access to oral ART. Greater understanding of PLHIV who use drugs\u2019 perspectives on LA-ART will be essential to fully leverage treatment advances and maximize its individual- and population-level benefits.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec017\">\n<jats:title>Methods<\/jats:title>\n<jats:p>From February 2019 to February 2020, we conducted in-depth interviews with 33 PLHIV who use drugs in Vancouver, Canada with suboptimal ART adherence (i.e., \u2266\u2009 50%). Participants were recruited for interviews through a prospective cohort study. Interviews were audio-recorded, transcribed, and analyzed using inductive and deductive approaches.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec018\">\n<jats:title>Results<\/jats:title>\n<jats:p>Our analysis identified key factors shaping LA-ART acceptability. First, LA-ART enthusiasm was highest among participants who were less satisfied with oral ART regimens due to pill burden or adverse side effects for oral ART and participants who struggled with daily adherence due substance use and social-structural factors (e.g., homelessness, incarceration). Moreover, participants who had physicians they trusted identified their physicians as credible sources of information on LA-ART, and indicated a desire for informed and shared decision-making regarding treatment changes. Finally, participants emphasized that there is no one-size-fits-all treatment approach for PLHIV who use drugs and highlighted the importance of access to a full range of available treatment options, including LA-ART.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec019\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>There is potential for high LA-ART uptake among PLHIV who use drugs, particularly those who experience adherence barriers due to their substance use and structural vulnerability. While our findings are limited by the specific population and setting, they nevertheless underscore the need for efforts to ensure universal and equitable access to LA-ART.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0319010","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:22:52Z","timestamp":1740766972000},"page":"e0319010","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Acceptability of long-acting antiretroviral therapy among people living with HIV who use drugs in Vancouver, Canada: A qualitative study"],"prefix":"10.1371","volume":"20","author":[{"given":"Koharu Loulou","family":"Chayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Brohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-3485","authenticated-orcid":true,"given":"Manal","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7608-7921","authenticated-orcid":true,"given":"Morgan","family":"Philbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra B.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-0764","authenticated-orcid":true,"given":"Ryan","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"9061","key":"pone.0319010.ref001","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(05)62505-6","article-title":"Decline in deaths from AIDS due to new antiretrovirals","volume":"349","author":"RS Hogg","year":"1997","journal-title":"Lancet"},{"key":"pone.0319010.ref002","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S2666-7568(22)00063-0","article-title":"Life expectancy of people with HIV on long-term antiretroviral therapy in Europe and North America: a cohort study","volume":"3","author":"A Trickey","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"8","key":"pone.0319010.ref003","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Antiretroviral Therapy Cohort Collaboration","year":"2017","journal-title":"Lancet HIV"},{"issue":"4","key":"pone.0319010.ref004","first-page":"242","article-title":"Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks","volume":"22","author":"SS Sutton","year":"2016","journal-title":"Am J Manag Care"},{"issue":"15","key":"pone.0319010.ref005","doi-asserted-by":"crossref","first-page":"e3361","DOI":"10.1097\/MD.0000000000003361","article-title":"Adherence to antiretroviral therapy and virologic failure: a meta-analysis","volume":"95","author":"WM Bezabhe","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"pone.0319010.ref006","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1360-0443.2008.02269.x","article-title":"Adherence to antiretroviral therapy for human immunodeficiency virus\/acquired immune deficiency syndrome among drug users: a systematic review","volume":"103","author":"M Malta","year":"2008","journal-title":"Addiction"},{"issue":"1","key":"pone.0319010.ref007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12889-018-6314-8","article-title":"Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions","volume":"19","author":"AR Bazzi","year":"2019","journal-title":"BMC Public Health"},{"issue":"4","key":"pone.0319010.ref008","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society\u2013USA panel","volume":"320","author":"MS Saag","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"pone.0319010.ref009","doi-asserted-by":"crossref","first-page":"e0246999","DOI":"10.1371\/journal.pone.0246999","article-title":"A qualitative investigation of HIV treatment dispensing models and impacts on adherence among people living with HIV who use drugs","volume":"16","author":"T Fleming","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"pone.0319010.ref010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10461-016-1470-2","article-title":"Antiretroviral therapy interruption among HIV positive people who use drugs in a setting with a community-wide HIV treatment-as-prevention initiative","volume":"21","author":"R McNeil","year":"2017","journal-title":"AIDS Behav"},{"issue":"10","key":"pone.0319010.ref011","doi-asserted-by":"crossref","first-page":"e25785","DOI":"10.1002\/jia2.25785","article-title":"\u201cIt\u2019s a burden, it\u2019s a nuisance. I wish I didn\u2019t have these other ailments\u201d: a qualitative exploration of comorbidities management among older people living with HIV who use drugs in Vancouver, British Columbia","volume":"24","author":"KL Chayama","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"pone.0319010.ref012","first-page":"S142\u20137","article-title":"Association between diagnoses of chronic noncancer pain, substance use disorder, and HIV-related outcomes in people living with HIV","volume":"82","author":"C Denis","year":"2019","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"3","key":"pone.0319010.ref013","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11904-014-0220-1","article-title":"Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis","volume":"11","author":"OA Uthman","year":"2014","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"4","key":"pone.0319010.ref014","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/01459740.2011.576725","article-title":"Structural vulnerability and health: Latino migrant laborers in the United States","volume":"30","author":"J Quesada","year":"2011","journal-title":"Med Anthropol"},{"issue":"9","key":"pone.0319010.ref015","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1080\/09540121.2015.1032205","article-title":"Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting","volume":"27","author":"B Joseph","year":"2015","journal-title":"AIDS Care"},{"issue":"9","key":"pone.0319010.ref016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11908-018-0636-7","article-title":"Substance use and adherence to antiretroviral therapy: what is known and what is unknown","volume":"20","author":"ME Socias","year":"2018","journal-title":"Curr Infect Dis Rep"},{"issue":"3","key":"pone.0319010.ref017","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s10461-016-1315-z","article-title":"Residential eviction and risk of detectable plasma HIV-1 RNA viral load among HIV-positive people who use drugs","volume":"21","author":"MC Kennedy","year":"2017","journal-title":"AIDS Behav"},{"issue":"9","key":"pone.0319010.ref018","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1007\/s10461-019-02547-z","article-title":"Criminal justice system involvement as a risk factor for detectable plasma HIV viral load in people who use illicit drugs: a longitudinal cohort study","volume":"23","author":"S Ickowicz","year":"2019","journal-title":"AIDS Behav"},{"issue":"4","key":"pone.0319010.ref019","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/QAI.0b013e3182433288","article-title":"Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy","volume":"59","author":"M-J Milloy","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"18","key":"pone.0319010.ref020","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1097\/QAD.0000000000000853","article-title":"Socioeconomic marginalization and plasma HIV-1 RNA nondetectability among individuals who use illicit drugs in a Canadian setting","volume":"29","author":"LA Richardson","year":"2015","journal-title":"AIDS"},{"key":"pone.0319010.ref021","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12981-016-0108-9","article-title":"Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study","volume":"13","author":"W Small","year":"2016","journal-title":"AIDS Res Ther"},{"issue":"2","key":"pone.0319010.ref022","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkab324","article-title":"Long-acting antiretrovirals: a new era for the management and prevention of HIV infection","volume":"77","author":"P Thoueille","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"pone.0319010.ref023","doi-asserted-by":"crossref","first-page":"e26126","DOI":"10.1002\/jia2.26126","article-title":"Advancing use of long-acting and extended delivery HIV prevention and treatment regimens","volume":"26","author":"S Delany-Moretlwe","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"pone.0319010.ref024","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S2352-3018(23)00134-0","article-title":"Long-acting antiretrovirals: research and implementation considerations in Africa","volume":"10","author":"C Norcross","year":"2023","journal-title":"Lancet HIV"},{"issue":"12","key":"pone.0319010.ref025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"S Swindells","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0319010.ref026","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"C Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0319010.ref027","doi-asserted-by":"crossref","first-page":"20503121231223600","DOI":"10.1177\/20503121231223600","article-title":"Advances in the transdermal delivery of antiretroviral drugs","volume":"12","author":"LW Limenh","year":"2024","journal-title":"SAGE Open Med"},{"issue":"9","key":"pone.0319010.ref028","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","article-title":"Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research","volume":"17","author":"DA Cobb","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"issue":"7","key":"pone.0319010.ref029","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"M Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"issue":"3","key":"pone.0319010.ref030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/COH.0000000000000734","article-title":"Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review","volume":"17","author":"O Sued","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"pone.0319010.ref031","doi-asserted-by":"crossref","first-page":"e0234666","DOI":"10.1371\/journal.pone.0234666","article-title":"\u201cA dream come true\u201d: perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania","volume":"15","author":"D Kerrigan","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"pone.0319010.ref032","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/apc.2020.0164","article-title":"A qualitative exploration of women\u2019s interest in long-acting injectable antiretroviral therapy across six cities in the women\u2019s interagency HIV study: intersections with current and past injectable medication and substance use","volume":"35","author":"MM Philbin","year":"2021","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"pone.0319010.ref033","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12954-023-00730-z","article-title":"Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and\/or housing instability","volume":"20","author":"L Fletcher","year":"2023","journal-title":"Harm Reduct J"},{"issue":"11","key":"pone.0319010.ref034","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/nnm.12.214","article-title":"Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients","volume":"8","author":"J Williams","year":"2013","journal-title":"Nanomedicine (Lond)"},{"key":"pone.0319010.ref035","first-page":"100603","article-title":"Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: a qualitative study","volume":"31","author":"SE Rutstein","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"pone.0319010.ref036","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s11524-023-00755-6","article-title":"Perceptions of long-acting injectable antiretroviral therapy among people living with HIV who use drugs and service providers: a qualitative analysis in Rhode Island","volume":"100","author":"AB Collins","year":"2023","journal-title":"J Urban Health"},{"key":"pone.0319010.ref037","article-title":"The role of cannabis in pain management among people living with HIV who use drugs: a qualitative study","author":"K Chayama","year":"2021","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"pone.0319010.ref038","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12954-023-00862-2","article-title":"Housing-based syringe services programs to improve access to safer injecting equipment for people who inject drugs in Vancouver, Canada: a spatially oriented qualitative study","volume":"20","author":"K Chayama","year":"2023","journal-title":"Harm Reduct J"},{"key":"pone.0319010.ref039","doi-asserted-by":"crossref","first-page":"102729","DOI":"10.1016\/j.drugpo.2020.102729","article-title":"Home and health among people living with HIV who use drugs: a qualitative study","volume":"80","author":"T Fleming","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"1","key":"pone.0319010.ref040","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1186\/s12889-020-09202-6","article-title":"Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada","volume":"20","author":"T Fleming","year":"2020","journal-title":"BMC Public Health"},{"issue":"8","key":"pone.0319010.ref041","doi-asserted-by":"crossref","first-page":"F59","DOI":"10.1097\/00002030-199708000-00001","article-title":"Needle exchange is not enough: lessons from the Vancouver injecting drug use study","volume":"11","author":"SA Strathdee","year":"1997","journal-title":"AIDS"},{"key":"pone.0319010.ref042","volume-title":"Research design: qualitative, quantitative, and mixed methods approaches","author":"J Creswell","year":"2009"},{"issue":"3","key":"pone.0319010.ref043","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/QAI.0000000000002337","article-title":"Multisite study of women living with HIV\u2019s perceived barriers to, and interest in, long-acting injectable antiretroviral therapy","volume":"84","author":"M Philbin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0319010.ref044","volume-title":"StatPearls [Internet]","author":"D Varghese","year":"2024"},{"issue":"1","key":"pone.0319010.ref045","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1136\/bmj.e256","article-title":"Shared decision making: really putting patients at the centre of healthcare","volume":"344","author":"AM Stiggelbout","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"pone.0319010.ref046","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/09540120220097900","article-title":"HIV\/AIDS patient involvement in antiretroviral treatment decisions","volume":"14","author":"WD Marelich","year":"2002","journal-title":"AIDS Care"},{"issue":"1","key":"pone.0319010.ref047","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/apc.1999.13.29","article-title":"\u201cMaking all the difference in the world\u201d: how physicians can help HIV-seropositive patients become more involved in their healthcare","volume":"13","author":"B Gerbert","year":"1999","journal-title":"AIDS Patient Care STDS"},{"issue":"8","key":"pone.0319010.ref048","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s11606-007-0241-1","article-title":"Is patients\u2019 preferred involvement in health decisions related to outcomes for patients with HIV?","volume":"22","author":"MC Beach","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"3","key":"pone.0319010.ref049","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09540120220123694","article-title":"Perceptions of HAART among gay men who declined a treatment offer: preliminary results from an interview-based study","volume":"14","author":"V Cooper","year":"2002","journal-title":"AIDS Care"},{"key":"pone.0319010.ref050","author":"A Thayaparan","year":"2023"},{"key":"pone.0319010.ref051","unstructured":"BC Centre for Excellence in HIV\/AIDS. RE: Cabotegravir and Rilpivirine extended-release injectable suspensions [Internet]. 2023. Available from: https:\/\/www.bccfe.ca\/sites\/default\/files\/uploads\/dear-doctor-letters\/cabenuva_cfe_2022-09-22.pdf"},{"key":"pone.0319010.ref052","author":"UNAIDS J","year":"2022"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:23:14Z","timestamp":1740766994000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319010"}},"subtitle":[],"editor":[{"given":"Hamufare Dumisani","family":"Mugauri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0319010","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}